In 2008, the FDA approved exenatide extended release for the treatment of type 2 diabetes. The drug was developed by Amylin Pharmaceuticals and is a once-weekly injection of exenatide. Bydureon (exenatide extended release) is an injectable medication used to treat type 2 diabetes. It is a long-acting form of exenatide, a drug that belongs to a class of drugs called incretin mimetics. Incretins are hormones that are released from the intestine in response to food. They increase insulin secretion and decrease glucagon secretion. Exenatide mimics the effects of incretins. In 2012, the FDA approved a new formulation of Bydureon that is easier to use than the original formulation.
Victoza is a medication that was first approved in 2010. It is used to treat type 2 diabetes. The medication works by helping the body to better use insulin. Victoza is a once-daily injection that is taken subcutaneously. The medication is available in a pen or vial. The cost of Victoza varies depending on the pharmacy, but it is typically around $500 for a month supply.
There is no clear winner between Bydureon and Victoza. Both drugs are effective at treating diabetes, but they have different side effects and costs.